Classes
DEA Class; Rx
Common Brand Names; Alfutral, UroXatral, Xatral
- BPH, Alpha Blockers
Description
Oral alpha-1 adrenergic blocker
Used to treat benign prostatic hypertrophy (BPH) in adult males
Similar to tamsulosin, alfuzosin appears to be more specific for alpha-1a receptors than other alpha-blockers
Indications
Contraindications
Hypersensitivity
Moderate to severe liver impairment
Coadministration with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) or other alpha1-blocking agents
Adverse Effects
- Abdominal pain (1-2%)
- Back pain (1-2%)
- Brochitis (1-2%)
- Constipation (1-2%)
- Dizziness (5.7%)
- Dyspepsia (1-2%)
- Fatigue (2.7%)
- Headache (3%)
- Impotence (1-2%)
- Nausea (1-2%)
- Pharyngitis (1-2%)
- URT infection (3%)
- Sinusitis (1-2%)
- Upper respiratory infection (3%)
- General disorders: Edema
- Cardiac disorders: Tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation
- Gastrointestinal disorders: Diarrhea, vomiting
- Hepatobiliary disorders: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)
- Upper respiratory system: Rhinitis
- Reproductive system: Priapism
- Dermatology: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis
- Vascular disorders: Flushing
- Blood and lymphatic system disorders: Thrombocytopenia
Warnings
Caution in coronary artery disease, liver disease, symptomatic orthostatic hypotension or coadministration with other drugs that lower blood pressure
May cause syncope (first-dose effect)
Discontinue treatment if angina occurs or worsens
Rule out prostate cancer before initiating therapy (symptoms similar)
Priapism may occur with use
Rule out prostate cancer prior to treatment
Caution with renal impairment (ieg, CrCl <30 mL/min)
Caution with history of prolonged QT syndrome (shown to prolong QT interval)
Intraoperative floppy iris syndrome during cataract surgery reported Advise patient regarding risk of priapism
Do not chew or crush tablets
Not for use as antihypertensive drugDrug is not indicated for use in women; there are no adequate data on developmental risk associated with use in pregnant women
Pregnancy and Lactation
Drug is not indicated for use in women; there are no adequate data on developmental risk associated with use in pregnant women
Drug is not indicated for use in women; there are no data on presence in human milk, effect on breastfed child, or on milk production
Maximum Dosage
10 mg/day PO.
10 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
How supplied
Alfuzosin hydrochloride
tablet, extended release
10mg
